New Cisplatin Analogues in Development: A Review

Drugs

Volumn 46, Issue 3, 1993, Pages 360-377

  Weiss, Raymond B ^a,b   Christian, Michaele C ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; CARBOPLATIN; CHOLINE ACETYLTRANSFERASE; CISPLATIN; CISPLATIN DERIVATIVE; CYTARABINE; DNA; DOXORUBICIN; ENLOPLATIN; IPROPLATIN; LOBAPLATIN; MIBOPLATIN; NEDAPLATIN; OXALIPLATIN; PLATINUM; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PLATINUM COMPLEX; PLATINUM DERIVATIVE; SATRAPLATIN; SEBRIPLATIN; SPIROPLATIN; TETRAPLATIN; TRK 710; UNCLASSIFIED DRUG; VINBLASTINE; ZENIPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW SUPPRESSION; CANCER THERAPY; CYTOTOXICITY; DIURESIS; DNA SYNTHESIS; DRUG EFFICACY; DRUG RESEARCH; DRUG RESISTANCE; DYSESTHESIA; GAIT DISORDER; GERM CELL TUMOR; HUMAN; HYDRATION; LARYNX SPASM; LEUKEMIA; LEUKEMIA CELL LINE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAT; REVIEW; VOMITING;

ADMINISTRATION, ORAL; ANIMAL; BIOLOGICAL AVAILABILITY; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS; HUMAN; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0027427932     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199346030-00003     Document Type: Review

References (109)

1. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer
2. Toxicological and tumoricidal evaluations of a new platinum complex, (−)-(R)2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato) platinum (II) monohydrate, in rats
3. Potent antitumour activity of (−)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato) platinum (II) monohydrate (DWA2114R) against advanced L1210 leukaemia in mice
4. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer
5. Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum (IV) stereoisomers of 1,2 diaminocyclohexanes
6. A phase I study of DWA2114R
7. Characterization of a ds-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogs
8. cis-diamminedichloroplatinum (II) (cisplatin) alters microtubule assembly dynamics
9. Circadian rhythm in toxicities and tissue uptake of 1,2 diamminocyclohexane (trans-1) oxalatoplatinum (II) in mice
10. Neurotoxicity (NTX) of long term oxaliplatin (L-OHP) therapy. Abstract 2421
11. Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives
12. Lack of crossresistance between certain platinum coordination compounds in mouse leukemia
13. JM 216: A novel orally active platinum complex. Abstract 3203
14. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate
15. Phase I study of a new water soluble platinum containing antitumor agent CL 287, 110 in advanced cancer patients. Abstract 1127
16. Studies on the antitumor activity of Group VIII transition metal complexes. Part 1. Platinum (II) complexes
17. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex
18. Characterization of the adclucts produced in DNA by cis-diamminedichloroplatinum (II) and cis-dichloro-(ethylenediamine) platinum (II)
19. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II)
20. cis-Diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer
21. Phase I study of oxaliplatin in patients with advanced cancer
22. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action
23. 3. Chirality and leaving-group ability of sulfoxide affecting biological activity
24. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequencing specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues
25. Prevention of cisplatin neurotoxicity with an ACTH(4–9)analogue in patients with ovarian cancer
26. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days/British
27. Cisplatin/carboplatin cross-resistance in ovarian cancer
28. Liposomes in drug delivery: clinical, diagnostic and ophthalmic potential
29. Neurotoxic side-effects of cisplatin
30. Cellular pharmacology of liposome-entrapped cis-bis-neodecanoato trans,R,R-1,2-diaminocyclohexane platinum (L-NDDP) in A2780 and A2780/PDD human overian carcinoma cells. Abstract 2414
31. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs
32. Antitumor, toxic and biochemical properties of cisplatin and eight other platinum complexes
33. Platinum coordination complexes which circumvent cisplatin resistance
34. New platinum drugs capable of oral administration. Abstract 231
35. A novel class of orally active platinum IV coordination complexes which circumvent cisplatin resistance in vitro. Abstract 2546
36. In vitro antitumor activity of lobaplatin (LOB) in cisplatin (DDP) sensitive and resistant human carcinoma cell lines (HCCL). Abstract 194
37. Diamminedichlo-roplatinum: a phase I study showing responses in testicular and other tumors
38. Inhibition of brain choline acetyltransferase by tetraplatin
39. Mechanistic studies of a novel class of trisubstituted platinum (II) antitumor agents
40. Ototoxicity of cis-diammine glycolato platinum, 254-S
41. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors
42. Circadian triming of cancer chemotherapy
43. A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers
44. Sequence-dependent termination of mammalian DNA polymerase reaction by a new platinum compound, (−)-(R)-2-amino-methylpyrrolidine (1,1-cyclobutane-dicarboxylato)-2-platinum (II) monohydrate)
45. Zeniplatin, (CL 286,558), an active new platinum analog in advanced non-small cell lung cancer (NSCLC): a phase II study. Abstract 929
46. Phase III study of DWA2114R for ovarian cancer
47. The activity of ammine/amine platinum (IV) dicarboxylates against cisplatin acquired-resistant human tumor cell lines. Abstract 75
48. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line
49. Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines
50. Circumvention of transport-mediated acquired cisplatin resistance in human cancer cell lines by the orally active platinum drug, Bis-acetatoammine dichloro(cyclohexylamine) platinum (IV) (JM216). Abstract 2383
51. Phase I clinical trial and pharmacokinetics of 4’-carboxyphthalato-(1,2-diaminocyclohexane) platinum (II)
52. Toxicity and antitumor activity of cis-bis-carboxylato (trans-R,R-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes
53. Chemical and biological studies on trans-R,R-1,2-diaminocyclohexane platinum (IV) compounds. Abstract 2416
54. Antitumor activity of platinum (II) complexes of 1,2 diammino-cyclohexane isomers
55. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861
56. Inhibition of Dunning ascitic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875)
57. Preclinical antitumor activity of CI-973, [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2 methyl-1,4-butane-diamine-N,N’) platinum
58. Phase II study of enloplatin for patients (Pts) with advanced ovarian cancer. Abstract 863
59. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer
60. 2 (4-methylpyridine) Cl] Cl, does not form N7,N7-d(GpG) chelates with DNA. An unexpected preference for platinum binding at the 5’G in d(GpG)
61. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump
62. Clinical studies with cisplatin analogues, 254S, DWA2114R and NK121
63. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum
64. Comparison of the antitumor effects and nephrotoxicityinducing activities of two new platinum complexes, (−)-(R)-2-aminomethylpyrrolidine(1,1-eyclobutanedicarboxylato)-platinum (II) monohydrate, and its enantiomeric isomer
65. Intracellular biotransformation of platinum compounds with the 1,2 diaminocyclohexane carrier ligand in the L1210 cell line
66. Lack of nephrotoxicity of orally administered mixed amine/amine platinum IV dicarboxylate complexes in rodents. Abstract 211
67. Acute toxicology of orally administered bis-aceto-ammine dichloro (cyclohexylamine) platinum IV (JM 216) in rodents. Abstract 3197
68. Phase I study of orally administered ammine diacetodichloro (cyclohexylamine) platinum (Pt) (IV) (po JM216). Abstract 320
69. Antitumor activity of TRK-710, a new platinum complex having activity against cisplatin-resistant tumors. Abstract 2378
70. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(−)-1,1-cyclobutane dicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice — a comparison with cis-diammine-dichloroplatinum (CDDP)
71. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule
72. Neurotoxicity of ormaplatin (NSC 363812) in a phase I trial of a daily times five schedule. Abstract 348
73. A pilot phase II study of zeniplatin in metastatic melanoma. Abstract 345
74. High-dose cisplatin in hypertonic saline in refractory ovarian cancer
75. Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum (II) on DNA
76. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines
77. Increased cytotoxicity and reversal of resistance to cis-diamminedichloro platinum (II) with entrapment of cis-Bisneodecanoato-trans-R,R-1,2 diamminecyclohexaneplatinum (II) in multilamellar lipid vesicles
78. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato- trans-R,R-1,2-diaminocyclohexane platinum (II)
79. Lipophilic cisplatin analogs entrapped in liposomes: role of chemical structure and liposome composition. Abstract 2425
80. Phase I trial of intraperitoneal (ip) ormaplatin (OP) with extended pharmacokinetic assessment. Abstract 2399
81. Antitumor activity and toxicity of cisplatin analogs
82. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes
83. The successful regression of large solid sarcoma 180 tumors by platinum compounds
84. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode
85. Platinum compounds: a new class of potent antitumor agents
86. Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia
87. Cisplatin resistance in human cancers
88. cis-dichlorodiammineplatinum (II) (NSC-119875): preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice
89. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support
90. Phase II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer
91. Phase I/pharmacokinetic study of ormaplatin (tetraplatin, NSC363812) on a day 1 and 8 schedule. Abstract 3211
92. Structural aspects of platinum anticancer drug interactions with DNA
93. Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum (II)
94. Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat
95. The response to chemotherapy of a variety of human tumour xenografts
96. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers
97. Multicenter phase II study of spiroplatm
98. Phase I study of spiroplatin
99. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2 diaminocyclohexane) platinum (II): new experimental data
100. 1) platinum in patients with metastatic solid tunours
101. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer
102. Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs
103. Phase I trial of ormaplatin (tetraplatin). Abstract 339
104. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study
105. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex
106. JM8, successor to cisplatin in advanced ovarian carcinoma? Correspondence
107. Plasma clearance and DNA cross-links in blood cells of CI-973 in leukemic patients. Abstract 2408